朗玛信息(300288) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥119,371,734.04, representing a year-on-year increase of 2.24%[6] - The net profit attributable to shareholders for Q3 2023 was ¥19,718,490.41, a decrease of 4.71% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥18,523,060.00, down 8.17% year-on-year[6] - Total operating revenue for Q3 2023 was CNY 347,570,680.13, a slight increase from CNY 340,285,859.67 in Q3 2022, representing a growth of approximately 2.4%[27] - Operating profit for the period reached CNY 81,922,981.00, compared to CNY 70,744,558.38 in the same period last year, indicating an increase of about 15.4%[28] - Net profit attributable to shareholders of the parent company was CNY 61,327,709.17, up from CNY 60,540,047.63 in Q3 2022, reflecting a growth of approximately 1.3%[28] - The company reported a total profit of CNY 71,145,139.74 for the quarter, slightly up from CNY 70,443,695.98 in Q3 2022, indicating a growth of approximately 1%[28] - The total comprehensive income attributable to the parent company was CNY 61,327,709.17, compared to CNY 60,540,047.63 in the previous period, reflecting an increase of approximately 1.3%[29] Cash Flow and Assets - Cash flow from operating activities for the year-to-date period reached ¥59,061,118.56, an increase of 55.94%[6] - The company's cash and cash equivalents increased to ¥375,637,253.11 from ¥332,766,572.15, representing a growth of approximately 12.4%[24] - The company's cash and cash equivalents at the end of Q3 2023 were CNY 292,829,976.93, an increase from CNY 231,577,091.43 in Q3 2022, reflecting a growth of approximately 26.5%[26] - The ending balance of cash and cash equivalents was CNY 375,316,136.66, up from CNY 307,326,851.20 at the end of the previous period, reflecting an increase of approximately 22.1%[31] - The net cash flow from operating activities was CNY 59,061,118.56, up from CNY 37,873,644.52 in the same period last year, representing a significant increase of approximately 56.5%[31] - The total cash inflow from operating activities was CNY 383,481,605.84, slightly down from CNY 385,417,994.64, indicating a decrease of about 0.5%[31] - The cash outflow from operating activities totaled CNY 324,420,487.28, compared to CNY 347,544,350.12 in the previous period, showing a decrease of approximately 6.7%[31] - The net cash flow from investing activities was negative at CNY -8,577,719.32, a decline from a positive CNY 17,132,951.05 in the previous year[31] - The cash flow from financing activities resulted in a net outflow of CNY -6,697,084.75, compared to a net outflow of CNY -107,718,146.14 in the same period last year, indicating an improvement[31] Assets and Liabilities - Total assets at the end of Q3 2023 amounted to ¥1,967,651,793.58, reflecting a growth of 6.40% from the end of the previous year[6] - The total assets of the company as of September 30, 2023, are ¥1,967,651,793.58, up from ¥1,849,235,259.72, indicating an increase of approximately 6.4%[24] - Non-current assets increased to ¥1,496,105,989.34 from ¥1,427,674,436.02, reflecting a growth of about 4.8%[24] - Total liabilities as of Q3 2023 amounted to CNY 348,516,184.19, up from CNY 288,386,237.65 in Q3 2022, representing an increase of approximately 20.9%[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 44,803[18] - The largest shareholder, Wang Wei, holds 32.10% of shares, totaling 108,496,015 shares[18] - The company reported a total of 81,892,436 restricted shares held by Wang Wei[18] Research and Development - Research and development expenses grew by 60.17% year-on-year, indicating increased investment in R&D projects[14] - Research and development expenses increased significantly to CNY 30,724,178.57, compared to CNY 19,182,025.84 in the previous year, marking an increase of about 60.1%[27] - The company is developing the "39AI General Practitioner" product, which utilizes extensive medical data and advanced algorithms for clinical diagnosis support[21] - The company has initiated the filing process for the "39AI General Practitioner" product's algorithms and models, with the launch date yet to be determined[21] - The company has not disclosed any information regarding the future launch of the "39AI General Practitioner" product[21] Other Financial Metrics - Basic and diluted earnings per share remained stable at CNY 0.18, unchanged from the previous period[29] - The company reported a decrease in cash paid for operating activities, which totaled CNY 141,693,374.06, down from CNY 146,162,155.13, indicating a decrease of about 3.2%[31] - The company has not undergone an audit for the third quarter report[33]